Invivyd (IVVD) Total Current Liabilities (2020 - 2026)
Invivyd's (IVVD) quarterly Total Current Liabilities came in at $31.0 million in Q2 2026, down 30.2% on a YoY basis from $44.5 million in Q2 2025, and down 9.18% quarter-over-quarter from $34.2 million in Q4 2025.
Analysis
Invivyd (IVVD) Total Current Liabilities (2020 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Total Current Liabilities for 7 consecutive years, with $31.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Total Current Liabilities fell 30.2% year-over-year to $31.0 million; the trailing twelve-month figure through Jun 2026 stood at $31.0 million (down 30.2% YoY), and the FY2025 full-year result was $34.2 million, down 44.88% from the prior year.
- Total Current Liabilities eased to $31.0 million in Q2 2026 per IVVD's latest filing, from $34.2 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $95.5 million in Q1 2022 and bottomed at $22.1 million in Q1 2023.
- Historically, Total Current Liabilities has averaged $46.1 million across 5 years, with a median of $44.5 million in 2025.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities plunged 76.91% in 2023, then jumped 193.17% in 2024.
- Over 5 years, Total Current Liabilities stood at $25.0 million in 2022, then soared by 100.91% to $50.3 million in 2023, then gained by 23.23% to $62.0 million in 2024, then sank by 44.88% to $34.2 million in 2025, then declined by 9.18% to $31.0 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $31.0 million, $34.2 million, and $44.5 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 25.50 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 11.02 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 3.94 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 5.53 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 1.58 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 2.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 3.92 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | 31.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 31.03 Mn |
| Dec 31, 2025 | 34.16 Mn |
| Sep 30, 2025 | 44.50 Mn |
| Jun 30, 2025 | 44.45 Mn |
| Mar 31, 2025 | 49.60 Mn |
| Dec 31, 2024 | 61.98 Mn |
| Sep 30, 2024 | 78.54 Mn |
| Jun 30, 2024 | 36.70 Mn |
| Mar 31, 2024 | 36.35 Mn |
| Dec 31, 2023 | 50.29 Mn |
| Sep 30, 2023 | 26.79 Mn |
| Jun 30, 2023 | 32.51 Mn |
| Mar 31, 2023 | 22.06 Mn |
| Dec 31, 2022 | 25.03 Mn |
| Sep 30, 2022 | 46.13 Mn |
| Jun 30, 2022 | 67.88 Mn |
| Mar 31, 2022 | 95.53 Mn |
| Dec 31, 2021 | 62.06 Mn |
| Sep 30, 2021 | 53.05 Mn |
| Jun 30, 2021 | 37.90 Mn |